Endothelial Cell Dysfunction in Pulmonary Hypertension
NCT00098072 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27
Last updated 2026-05-22
Summary
This study will examine and test healthy volunteers and patients with pulmonary hypertension to try to learn more about the disease and find better ways to detect, treat, and, if possible, slow progression. Pulmonary hypertension is a rare blood vessel disorder of the lung in which the pressure in the pulmonary artery (the blood vessel that leads from the heart to the lungs) rises above normal levels and may become life-threatening.
Normal volunteers and patients with pulmonary hypertension 18 years of age and older may be eligible for this study. All candidates are screened with a review of their medical records. Normal volunteers also have a medical history, electrocardiogram, echocardiogram (heart ultrasound), and pulmonary function test, in which the subject breathes in and out of a tube that measures lung volume, mechanics and function.
All participants undergo the following tests and procedures:
* Echocardiogram to measure heart function and blood pressure in the lungs. A small probe held against the chest uses sound waves to obtain pictures of the heart.
* Magnetic resonance imaging (MRI) to evaluate the heart's pumping action. Subjects lie on a stretcher that slides into a long, tube-shaped scanner. The machine uses a magnetic field and radio waves to obtain images of the heart.
* 6-minute walk to measure how far the subject can walk in 6 minutes. Subjects walk around the hospital for 6 minutes at a comfortable pace.
* Exercise testing to measure the ability to exercise and the subject's oxygen levels during exercise. Subjects exercise on a bike or treadmill while the oxygen and carbon dioxide they breathe are measured using a small device placed in the mouth.
* Right heart catheterization to measure pressure in the heart and lungs. A small catheter (plastic tube) is placed in an arm vein. A longer catheter called a central line is placed in a deeper vein in the neck or just below the neck, or in the leg or arm. A long, thin catheter that measures blood pressure directly is then inserted into the vein and advanced through the chambers of the heart into the lung artery to measure all the pressures in the heart and obtain blood samples.
* Genetic and protein studies. DNA, RNA, and proteins from blood samples are studied for genes and proteins that might predict the development or progression of pulmonary hypertension.
In addition to the above, patients whose pulmonary hypertension was caused by a blood vessel injury undergo the tests described below. The right heart catheter inserted for the catheterization procedure remains in place to obtain measurements of the effects of nitric oxide and nitrite in the following procedures:
* Inhalation of nitric oxide (a gas naturally produced by cells lining arteries) at 30-minute intervals to examine its effect on lung and heart pressures.
* Inhalation of aerosolized nitrite at 5-minute intervals to measure its effects on lung and heart pressures.
* Inhalation of nitric oxide for up to 24 hours to obtain multiple measurements of its effect on lung and heart pressures.
* Blood draws for laboratory tests.
In patients whose pulmonary hypertension was caused by a blood vessel injury, we also plan to follow response to standard therapy. After the initiation of standard therapy, we will restudy the same parameters (excluding NO and sodium nitrite studies) in these patients at approximately 4 months, and yearly for 5 years
Conditions
- Secondary Pulmonary Arterial Hypertension
Interventions
- PROCEDURE
-
Heart Catheterization
Heart Catheterization and collection of samples
Sponsors & Collaborators
-
National Institutes of Health Clinical Center (CC)
lead NIH
Principal Investigators
-
Michael A Solomon, M.D. · National Institutes of Health Clinical Center (CC)
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-05-17
- Primary Completion
- 2009-07-08
- Completion
- 2009-07-08
Countries
- United States
Study Locations
More Related Trials
-
The Study Of CT Scans and Echo Parameters in Patients With PAH
NCT00625963 ·Status: COMPLETED
-
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies
NCT02959723 ·Status: UNKNOWN
-
Predictors of Pulmonary Hypertension in Patients With Advanced Lung Diseases
NCT02777957 ·Status: UNKNOWN
-
3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension
NCT02799979 ·Status: UNKNOWN
-
Prognostic Value of Estimated Plasma Volume in Pulmonary Hypertension
NCT05861479 ·Status: COMPLETED
-
Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging
NCT01461343 ·Status: COMPLETED ·Phase: NA
-
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH
NCT05618093 ·Status: WITHDRAWN ·Phase: NA
-
Pulmonary Embolism: Mechanism and Therapeutic Innovation
NCT05360992 ·Status: COMPLETED
-
Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers
NCT01600898 ·Status: COMPLETED
-
Exploring Blood Cell Function and Oxidative Stress to Improve Diagnosis and Treatment in Pre-Capillary Pulmonary Hypertension
NCT07176260 ·Status: RECRUITING
-
Dyspnea in Chronic Thromboembolic Pulmonary Hypertension
NCT03786367 ·Status: COMPLETED
-
Angiogenic Imaging in Pulmonary Arterial Hypertension
NCT03166306 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Thrombolytic and Interventional Treatment of Pulmonary Embolism
NCT03886194 ·Status: UNKNOWN ·Phase: NA
-
Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension
NCT01572077 ·Status: COMPLETED ·Phase: NA
-
The Prospective Risk Factor Evaluation & Discovery In CTEPH Study
NCT03470207 ·Status: UNKNOWN ·Phase: NA
-
Pulmonary Perfusion Heterogeneity in Patients With CTEPH Using Functional PET Imaging
NCT02114047 ·Status: COMPLETED
-
Acute Decompensation of Pulmonary Hypertension
NCT03926572 ·Status: COMPLETED ·Phase: NA
-
Contribution of Echocardiography to Prognostic Evaluation of Pulmonary Arterial Hypertension
NCT02885155 ·Status: COMPLETED
-
Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome
NCT02565030 ·Status: COMPLETED
-
Evaluation of the Prevalence of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease
NCT00434902 ·Status: UNKNOWN
-
Risk Stratification for Patients Presenting With Acute Pulmonary Embolism (PE)
NCT00562042 ·Status: TERMINATED
-
Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension
NCT02216279 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study Evaluating Heart and Lung Metabolism in Pulmonary Hypertension Associated With Left Heart Disease
NCT02237378 ·Status: TERMINATED ·Phase: NA
-
Prevalence and Risk Factors of Pulmonary Hypertension in Patients with Myeloproliferative Neoplasms in Assiut University Hospital.
NCT06647706 ·Status: NOT_YET_RECRUITING
-
Clinical, Radiological, Tissue and Biological Phenotyping for the Analysis of the Transition From Physiology to Pathology in Pulmonary Diseases With Pulmonary Hypertension
NCT07184671 ·Status: NOT_YET_RECRUITING